Key result
Edoxaban monotherapy resulted in a similar mean relative change in MRV-quantified thrombus volume compared to parenteral anticoagulation bridging to warfarin.
Why the study?
Does edoxaban monotherapy improve relative change in MRV-quantified thrombus volume compared to parenteral anticoagulation bridging to warfarin in patients with acute symptomatic proximal DVT?
RCT (n=85)
Open-label
2:1 allocation ratio
Yes
Does edoxaban monotherapy improve relative change in MRV-quantified thrombus volume compared to parenteral anticoagulation bridging to warfarin in patients with acute symptomatic proximal DVT?
MRV is a feasible surrogate imaging modality to assess thrombus volume changes in acute DVT, demonstrating similar volume reductions between edoxaban and standard anticoagulation.
Answers are grounded in this paper and cite their sources.
MRV feasible for serial thrombus volume assessment in acute DVT; leaves open its role in guiding anticoagulation choices.
The feasibility of magnetic resonance venography (MRV) for measuring change in thrombus volume with a novel anticoagulation regimen versus standard anticoagulation in patients with symptomatic deep vein thrombosis (DVT) has not been assessed. Our aim was to study the feasibility of MRV to measure change in thrombus volume in patients with acute symptomatic objectively confirmed proximal DVT in an open-label multicenter trial (edoxaban Thrombus Reduction Imaging Study, eTRIS). We randomized patients in a 2:1 allocation ratio to edoxaban 90 mg/day for 10 days followed by 60 mg/day versus parenteral anticoagulation bridging to warfarin for 3 months. The primary efficacy outcome was a surrogate end point of the relative change in MRV-quantified thrombus volume from baseline to Day 14-21. A total of 85 eligible patients from 26 study sites were randomized to edoxaban monotherapy (n=56) versus parenteral anticoagulation as a 'bridge' to warfarin (n=29). The mean relative change in MRV-quantified thrombus volume from baseline to Day 14-21 was similar in patients treated with edoxaban and parenteral anticoagulation as a 'bridge' to warfarin (-50.1% vs -58.9%; 95% confidence interval of treatment difference, -12.7%, 30.2%). However, thrombus extension was observed in eight patients in the edoxaban monotherapy group and in none in the warfarin group. Rates of recurrent venous thromboembolism (3.6% vs 3.6%, p=0.45) and clinically relevant non-major bleeding (5.4% vs 7.1%, p=0.34) were also similar. No major bleeds occurred in either on-treatment group during the study period. In conclusion, MRV can assess change in thrombus volume in patients with acute DVT randomized to two different anticoagulant regimens.ClinicalTrials.gov IDENTIFIER NCT01662908: INVESTIGATIONAL NEW DRUG IND APPLICATION EDOXABAN IND # 63266.
No takes yet. Share an insight, caveat, or question.
Piazza et al. (2016) conducted an RCT in Symptomatic deep vein thrombosis (DVT) (n=85). Edoxaban vs. Parenteral anticoagulation bridging to warfarin was evaluated on Relative change in MRV-quantified thrombus volume from baseline to Day 14-21 (treatment difference, 95% CI -12.7%, 30.2%). Edoxaban monotherapy resulted in a similar mean relative change in MRV-quantified thrombus volume compared to parenteral anticoagulation bridging to warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: